HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
cadralazine
structure given in first source
Also Known As:
ISF 2469
Networked:
21
relevant articles (
4
outcomes,
7
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridazines: 11
cadralazine: 21
Related Diseases
1.
Hypertension (High Blood Pressure)
01/01/1988 - "
The potent and long lasting hypotensive effect of cadralazine might be useful for the treatment of arterial hypertension.
"
09/01/1996 - "
It is concluded that arterial vasodilation with cadralazine reduces flow resistance in the circulatory system in hypertension and has acute rheologic effects that disappear during chronic medication.
"
01/01/1985 - "
Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
"
12/01/1989 - "
Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine.
"
11/01/1985 - "
The antihypertensive activity of a new arterial dilator, cadralazine, was evaluated in 40 patients with mild-to-moderate arterial hypertension.
"
2.
Heart Failure
02/01/1987 - "
The clinical and haemodynamic effects of a single oral dose of cadralazine were studied in 22 patients with an average age of 64 years presenting with severe chronic cardiac failure.
"
02/01/1987 - "
[Treatment of chronic cardiac failure with cadralazine.
"
02/01/1987 - "
This study shows the efficacy of a single 30 mg daily dose of cadralazine, an arterial vasodilator, in patients with severe cardiac failure.
"
02/01/1986 - "
[Efficacy and tolerability of a delayed-action vasodilator agent, cadralazine, in severe chronic cardiac failure].
"
3.
Essential Hypertension
01/01/1986 - "
Forearm venous tone and brachial artery hemodynamics, including determinations of the arterial diameter and compliance by the use of pulsed Doppler systems, were measured in 16 patients with sustained essential hypertension before and after acute oral cadralazine dosing.
"
01/01/1986 - "
Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension.
"
09/01/1996 - "
Since some antihypertensive drugs can affect blood rheology, the purpose of this study was to evaluate whether acute and long-term arterial vasodilation with cadralazine influences rheologic parameters in essential hypertension.
"
06/01/1986 - "
[Non-invasive study of the role of carotid distension in the baroreflex response to the arteriolar vasodilator cadralazine in essential hypertension].
"
01/01/1999 - "
Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension.
"
4.
Tachycardia (Tachyarrhythmias)
04/01/1994 - "
The hemodynamic study in responders showed that both cadralazine and chlorthalidone acted through a reduction of peripheral resistances without inducing reflex tachycardia.
"
01/01/1984 - "
Cadralazine reduced hypertension and bradycardia effects, increased hypotension and tachycardia responses, and caused a further increase in cardiac output and coronary blood flow.
"
5.
Hypertrophy
11/01/1997 - "
This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension.
"
Related Drugs and Biologics
1.
Vasodilator Agents (Vasodilators)
2.
Chlorthalidone (Chlortalidone)
3.
Atenolol (Tenormin)
4.
Salts
5.
Antihypertensive Agents (Antihypertensives)
6.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.
temocapril hydrochloride (temocapril)
8.
Nicorandil (SG 75)
9.
Nitrendipine
10.
Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
Related Therapies and Procedures
1.
Therapeutics
2.
Oral Administration